ArticleProteomics. Clinical applications2013
A versatile protein microarray platform enabling antibody profiling against denatured proteins.
Article in Proteomics. Clinical applications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Cell-Free Gene Expression: Methods and Applications.Chemical reviews · 2025Review
- Phage Immunoprecipitation Sequencing (PhIP-Seq) for Analyzing Antibody Epitope Repertoires Against Food Antigens.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: data from the Osteoarthritis Initiative.Annals of the rheumatic diseases · 2019Article
- The specific seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein.Scientific reports · 2019Article
- A Novel Mass Spectrometry Platform for Multiplexed N-Glycoprotein Biomarker Discovery from Patient Biofluids by Antibody Panel Based N-Glycan Imaging.Analytical chemistry · 2019Article
- Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis.Scientific reports · 2019Article
- Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes.Nature communications · 2019Article
- Autoantibody biomarkers for the detection of serous ovarian cancer.Gynecologic oncology · 2017Article
- Serum Immune Profiling for Early Detection of Cervical Disease.Theranostics · 2017Article
- Combination of OipA, BabA, and SabA as candidate biomarkers for predicting Helicobacter pylori-related gastric cancer.Scientific reports · 2016Article
- Mapping transcription factor interactome networks using HaloTag protein arrays.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.Proteomics. Clinical applications · 2016Article
- Review
- Article
- Proteomic Monitoring of B Cell Immunity.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Plasma Autoantibodies Associated with Basal-like Breast Cancers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- HaloTag technology: a versatile platform for biomedical applications.Bioconjugate chemistry · 2015Review
- HeLa Based Cell Free Expression Systems for Expression of Plasmodium Rhoptry Proteins.Journal of visualized experiments : JoVE · 2015Article
- NAPPA as a Real New Method for Protein Microarray Generation.Microarrays (Basel, Switzerland) · 2015Review
- Host-pathogen interaction profiling using self-assembling human protein arrays.Journal of proteome research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
purposeWe aim to develop a protein microarray platform capable of presenting both natural and denatured forms of proteins for antibody biomarker discovery. We will further optimize plasma screening protocols to improve detection. EXPERIMENTAL
designWe developed a new covalent capture protein microarray chemistry using HaloTag fusion proteins and ligand. To enhance protein yield, we used HeLa cell lysate as an in vitro transcription translation (IVTT) system. Escherichia coli lysates were added to the plasma blocking buffer to reduce nonspecific background. These protein microarrays were probed with plasma samples and autoantibody responses were quantified and compared with or without denaturing buffer treatment.
resultsWe demonstrated that protein microarrays using the covalent attachment chemistry endured denaturing conditions. Blocking with E. coli lysates greatly reduced the background signals and expression with IVTT based on HeLa cell lysates significantly improved the antibody signals on protein microarrays probed with plasma samples. Plasma samples probed on denatured protein arrays produced autoantibody profiles distinct from those probed on natively displayed proteins. CONCLUSIONS AND CLINICAL RELEVANCE: This versatile protein microarray platform allows the display of both natural and denatured proteins, offers a new dimension to search for disease-specific antibodies, broadens the repertoire of potential biomarkers, and will potentially yield clinical diagnostics with greater performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.